Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging?

Ben-Aharon I, Levi M, Margel D, Yerushalmi R, Rizel S, Perry S, Sharon E, Hasky N, Abir R, Fisch B, Tobar A, Shalgi R, Stemmer SM.

Oncotarget. 2018 Mar 23;9(22):15931-15941. doi: 10.18632/oncotarget.24638. eCollection 2018 Mar 23.

2.

Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.

Stemmer SM, Steiner M, Rizel S, Soussan-Gutman L, Ben-Baruch N, Bareket-Samish A, Geffen DB, Nisenbaum B, Isaacs K, Fried G, Rosengarten O, Uziely B, Svedman C, McCullough D, Maddala T, Klang SH, Zidan J, Ryvo L, Kaufman B, Evron E, Karminsky N, Goldberg H, Shak S, Liebermann N.

NPJ Breast Cancer. 2017 Sep 8;3:33. doi: 10.1038/s41523-017-0034-6. eCollection 2017.

3.

Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.

Stemmer SM, Steiner M, Rizel S, Geffen DB, Nisenbaum B, Peretz T, Soussan-Gutman L, Bareket-Samish A, Isaacs K, Rosengarten O, Fried G, McCullough D, Svedman C, Shak S, Liebermann N, Ben-Baruch N.

NPJ Breast Cancer. 2017 Sep 8;3:32. doi: 10.1038/s41523-017-0033-7. eCollection 2017.

4.

The association between smoking and breast cancer characteristics and outcome.

Goldvaser H, Gal O, Rizel S, Hendler D, Neiman V, Shochat T, Sulkes A, Brenner B, Yerushalmi R.

BMC Cancer. 2017 Sep 6;17(1):624. doi: 10.1186/s12885-017-3611-z.

5.

A Dedicated Follow-Up Clinic for BRCA Mutation Carriers.

Yerushalmi R, Rizel S, Zoref D, Sharon E, Eitan R, Sabah G, Grubstein A, Rafson Y, Cohen M, Magen A, Birenboim I, Margel D, Ozlavo R, Sulkes A, Brenner B, Perry S.

Isr Med Assoc J. 2016 Sep;18(9):549-552.

6.

Factors Affecting Communication Patterns between Oncology Staff and Family Members of Deceased Patients: A Cross-Sectional Study.

Granot T, Gordon N, Perry S, Rizel S, Stemmer SM.

PLoS One. 2016 Sep 28;11(9):e0162813. doi: 10.1371/journal.pone.0162813. eCollection 2016.

7.

The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics.

Goldvaser H, Rizel S, Hendler D, Neiman V, Shepshelovich D, Shochat T, Sulkes A, Brenner B, Yerushalmi R.

Int J Endocrinol. 2016;2016:4658469. doi: 10.1155/2016/4658469. Epub 2016 Aug 28.

8.

The Association between Angiotensin Receptor Blocker Usage and Breast Cancer Characteristics.

Goldvaser H, Rizel S, Hendler D, Neiman V, Shepshelovich D, Shochat T, Sulkes A, Brenner B, Yerushalmi R.

Oncology. 2016;91(4):217-223. Epub 2016 Aug 20.

PMID:
27544756
9.

Earlier Age of Breast Cancer Onset in Israeli BRCA Carriers-Is it a Real Phenomenon?

Agranat S, Baris H, Kedar I, Shochat M, Rizel S, Perry S, Margel D, Sulkes A, Yerushalmi R.

Breast J. 2016 Nov;22(6):662-666. doi: 10.1111/tbj.12653. Epub 2016 Aug 17.

PMID:
27533489
10.

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.

Lewin R, Sulkes A, Shochat T, Tsoref D, Rizel S, Liebermann N, Hendler D, Neiman V, Ben-Aharon I, Friedman E, Paluch-Shimon S, Margel D, Kedar I, Yerushalmi R.

Breast Cancer Res Treat. 2016 Jun;157(3):511-6. doi: 10.1007/s10549-016-3836-6. Epub 2016 May 25.

PMID:
27225387
11.

BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities in vitro and in vivo.

Uziel O, Yerushalmi R, Zuriano L, Naser S, Beery E, Nordenberg J, Lubin I, Adel Y, Shepshelovich D, Yavin H, Ben Aharon I, Pery S, Rizel S, Pasmanik-Chor M, Frumkin D, Lahav M.

Oncotarget. 2016 Jan 19;7(3):2433-54. doi: 10.18632/oncotarget.5693.

12.

Long-Term Follow-Up of Chemotherapy-Induced Ovarian Failure in Young Breast Cancer Patients: The Role of Vascular Toxicity.

Ben-Aharon I, Granot T, Meizner I, Hasky N, Tobar A, Rizel S, Yerushalmi R, Ben-Haroush A, Fisch B, Stemmer SM.

Oncologist. 2015 Sep;20(9):985-91. doi: 10.1634/theoncologist.2015-0044. Epub 2015 Jun 22.

13.

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR.

J Clin Oncol. 2015 May 10;33(14):1574-83. doi: 10.1200/JCO.2014.56.9590. Epub 2015 Mar 16.

PMID:
25779558
14.

Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.

Yerushalmi R, Goldvaser H, Sulkes A, Ben-Aharon I, Hendler D, Neiman V, Ciuraru NB, Bonilla L, Amit L, Zer A, Granot T, Rizel S, Stemmer SM.

PLoS One. 2014 Oct 15;9(10):e107273. doi: 10.1371/journal.pone.0107273. eCollection 2014.

15.

D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.

Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, Yelensky R, Brown M, Miller VA, Sarid D, Rizel S, Klein B, Rubinek T, Wolf I.

Cancer Res. 2013 Dec 1;73(23):6856-64. doi: 10.1158/0008-5472.CAN-13-1197. Epub 2013 Nov 11.

16.

Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.

Ben-Aharon I, Vidal L, Rizel S, Yerushalmi R, Shpilberg O, Sulkes A, Stemmer SM.

PLoS One. 2013 Aug 26;8(8):e70044. doi: 10.1371/journal.pone.0070044. eCollection 2013. Review.

17.

Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin.

Kundel Y, Nasser NJ, Purim O, Yerushalmi R, Fenig E, Pfeffer RM, Stemmer SM, Rizel S, Symon Z, Kaufman B, Sulkes A, Brenner B.

PLoS One. 2013 Jul 10;8(7):e68327. doi: 10.1371/journal.pone.0068327. Print 2013.

18.

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.

Stemmer SM, Klang SH, Ben-Baruch N, Geffen DB, Steiner M, Soussan-Gutman L, Merling S, Svedman C, Rizel S, Lieberman N.

Breast Cancer Res Treat. 2013 Jul;140(1):83-92. doi: 10.1007/s10549-013-2603-1. Epub 2013 Jun 26.

19.

Chemotherapy-induced ovarian failure as a prototype for acute vascular toxicity.

Ben-Aharon I, Meizner I, Granot T, Uri S, Hasky N, Rizel S, Yerushalmi R, Sulkes A, Stemmer SM.

Oncologist. 2012;17(11):1386-93. doi: 10.1634/theoncologist.2012-0172. Epub 2012 Sep 6.

20.

Tailoring neoadjuvant chemotherapy for locally advanced breast cancer: a historical prospective study.

Zer A, Rizel S, Braunstein R, Yerushalmi R, Hendler D, Neimann V, Cioreuru N, Sulkes A, Stemmer SM.

Chemotherapy. 2012;58(2):95-101. doi: 10.1159/000336257. Epub 2012 Feb 29.

PMID:
22377846
21.

Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study.

Hendler D, Rizel S, Yerushalmi R, Neiman V, Bonilla L, Braunstein R, Sulkes A, Stemmer SM.

Am J Clin Oncol. 2011 Dec;34(6):619-24. doi: 10.1097/COC.0b013e3181f94716.

PMID:
21217400
22.

Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes.

Bar-Joseph H, Ben-Aharon I, Rizel S, Stemmer SM, Tzabari M, Shalgi R.

Reprod Toxicol. 2010 Dec;30(4):566-72. doi: 10.1016/j.reprotox.2010.07.003. Epub 2010 Jul 23.

PMID:
20656019
23.

Doxorubicin-induced ovarian toxicity.

Ben-Aharon I, Bar-Joseph H, Tzarfaty G, Kuchinsky L, Rizel S, Stemmer SM, Shalgi R.

Reprod Biol Endocrinol. 2010 Mar 4;8:20. doi: 10.1186/1477-7827-8-20.

24.

Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study.

Yerushalmi R, Kramer MR, Rizel S, Sulkes A, Gelmon K, Granot T, Neiman V, Stemmer SM.

Ann Oncol. 2009 Mar;20(3):437-40. doi: 10.1093/annonc/mdn652. Epub 2009 Jan 12.

PMID:
19139179
25.

Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.

Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, Klein B, Geffen DB, Kaufman B.

Cancer. 2008 Feb 15;112(4):731-6.

26.

Radiation treatment for ductal carcinoma in situ (DCIS): is a boost to the tumor bed necessary?

Yerushalmi R, Sulkes A, Mishaeli M, Neumann A, Dinerman M, Sulkes J, Rizel S, Yarom N, Gutman H, Fenig E.

Neoplasma. 2006;53(6):507-10.

PMID:
17167720
27.

Vulvar cancer metastatic to the breast.

Vicus D, Korach J, Friedman E, Rizel S, Ben-Baruch G.

Gynecol Oncol. 2006 Dec;103(3):1144-6. Epub 2006 Sep 26.

PMID:
17005246
28.

Breast cancer in octogenarians.

Evron E, Goldberg H, Kuzmin A, Gutman R, Rizel S, Sella A, Gutman H.

Cancer. 2006 Apr 15;106(8):1664-8.

29.

Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.

Sade RB, Chetrit A, Figer A, Papa MZ, Flex D, Rizel S, Friedman E.

Eur J Cancer. 2006 Mar;42(5):650-5. Epub 2006 Feb 7.

PMID:
16464572
30.

Postoperative loco-regional radiation therapy for breast cancer patients with four or more involved lymph nodes or extracapsular extension.

Evron E, Barzily L, Rakowsky E, Ben-Baruch N, Sulkes J, Rizel S, Fenig E.

Isr Med Assoc J. 2005 Jul;7(7):439-42.

31.

Breast conservation after neoadjuvant chemotherapy.

Sadetzki S, Oberman B, Zipple D, Kaufman B, Rizel S, Novikov I, Papa MZ.

Ann Surg Oncol. 2005 Jun;12(6):480-7. Epub 2005 Apr 19.

PMID:
15868065
32.

High-dose chemotherapy and autologous stem cell transplant in women with de novo chemosensitive metastatic breast cancer.

Stemmer SM, Hardan I, Brenner HJ, Rizel S.

Am J Clin Oncol. 2004 Jun;27(3):250-5.

PMID:
15170143
33.

The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study.

Stemmer SM, Rizel S, Hardan I, Adamo A, Neumann A, Goffman J, Brenner HJ, Pfeffer MR.

J Clin Oncol. 2003 Jul 15;21(14):2713-8.

PMID:
12860949
34.

Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel.

Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T, Gershoni R, Rizel S, Struewing JP, Modan B.

Gynecol Oncol. 2003 Jun;89(3):494-8.

PMID:
12798717
35.

Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.

Stemmer SM, Hardan I, Raz H, Adamou AK, Inbar M, Gottfried M, Merrick Y, Cohen Y, Sulkes A, Ben-Baruch N, Pfeffer RP, Brenner HJ, Rizel S.

Bone Marrow Transplant. 2003 Apr;31(8):655-61.

PMID:
12692605
36.

CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups.

Ron IG, Wigler N, Borovik R, Peretz T, Rizel S, Shani A, Brenner J, Farbstein H, Brenner HJ, Chaitchik S, Catane R, Inbar MJ.

Am J Clin Oncol. 2002 Oct;25(5):520-2.

PMID:
12393997
37.

Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women.

Figer A, Karasik YP, Baruch RG, Chetrit A, Papa MZ, Sade RB, Rizel S, Friedman E.

Isr Med Assoc J. 2002 Oct;4(10):759-62. Erratum in: Isr Med Assoc J. 2003 May;5(5):389. Riezel Shulamith [corrected to Rizel Shulamith].

PMID:
12389335
38.

The Tyr978X BRCA1 Mutation in Non-Ashkenazi Jews: Occurrence in High-Risk Families, General Population and Unselected Ovarian Cancer Patients.

Shiri-Sverdlov R, Gershoni-Baruch R, Ichezkel-Hirsch G, Gotlieb WH, Bruchim Bar-Sade R, Chetrit A, Rizel S, Modan B, Friedman E.

Community Genet. 2001 Jul;4(1):50-55.

PMID:
11493753
39.

CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study.

Ron IG, Wigler N, Borovik R, Brufman G, Rizel S, Shani A, Brenner J, Farbstein H, Dale A, Inbar MJ, Brenner HJ, Chaitchik S, Catane R.

Am J Clin Oncol. 2001 Aug;24(4):323-7.

PMID:
11474254
40.

Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.

Stemmer SM, Pfeffer MR, Rizel S, Hardan I, Goffman J, Gezin A, Neumann A, Kitsios P, Alezra D, Brenner HJ.

Cancer. 2001 Jun 1;91(11):1983-91.

PMID:
11391576
41.

The psychosocial experience of women treated for breast cancer by high-dose chemotherapy supported by autologous stem cell transplant: a qualitative analysis of support groups.

Feigin R, Greenberg A, Ras H, Hardan Y, Rizel S, Ben Efraim T, Stemmer SM.

Psychooncology. 2000 Jan-Feb;9(1):57-68.

PMID:
10668060
42.

Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.

Shiri-Sverdlov R, Oefner P, Green L, Baruch RG, Wagner T, Kruglikova A, Haitchick S, Hofstra RM, Papa MZ, Mulder I, Rizel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E.

Hum Mutat. 2000 Dec;16(6):491-501.

PMID:
11102978
43.

Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma.

Ben-Baruch G, Sivan E, Moran O, Rizel S, Menczer J, Seidman DS.

Gynecol Oncol. 1996 Mar;60(3):393-6.

PMID:
8774644
44.

Intraperitoneal chemotherapy with cisplatin and etoposide in ovarian carcinoma patients who are clinically in complete remission.

Menczer J, Ben-Baruch G, Rizel S, Brenner H.

Eur J Gynaecol Oncol. 1995;16(1):12-7.

PMID:
7744111
45.
46.

Extraperitoneal metastases after intraperitoneal chemotherapy of ovarian cancer patients with a negative second-look laparotomy.

Menczer J, Ben-Baruch G, Rizel S, Brenner H.

Int J Gynecol Cancer. 1993 Nov;3(6):359-362.

PMID:
11578369
47.
48.

Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission.

Menczer J, Ben-Baruch G, Rizel S, Brenner H.

Gynecol Oncol. 1992 Aug;46(2):222-5.

PMID:
1500025
49.

Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study.

Menczer J, Ben-Baruch G, Rizel S, Brenner H.

Eur J Gynaecol Oncol. 1992;13(4):316-8.

PMID:
1516581
50.

Supplemental Content

Support Center